[go: up one dir, main page]

AR026631A1 - ''3-4-dihidroquinazolinas 5,6-disustituidas'' - Google Patents

''3-4-dihidroquinazolinas 5,6-disustituidas''

Info

Publication number
AR026631A1
AR026631A1 ARP000106257A ARP000106257A AR026631A1 AR 026631 A1 AR026631 A1 AR 026631A1 AR P000106257 A ARP000106257 A AR P000106257A AR P000106257 A ARP000106257 A AR P000106257A AR 026631 A1 AR026631 A1 AR 026631A1
Authority
AR
Argentina
Prior art keywords
formula
compound
patient
pharmaceutically acceptable
platelet count
Prior art date
Application number
ARP000106257A
Other languages
English (en)
Original Assignee
Roberts Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roberts Lab Inc filed Critical Roberts Lab Inc
Publication of AR026631A1 publication Critical patent/AR026631A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se ha encontrado que los compuestos de formula (1) (en donde X e Y, que pueden ser iguales o diferentes, representan cada uno Cl, Br, o F) y tautomeros delos mismos, tienen mejores propiedades de reduccion del recuento de plaquetas. También se propor cionan métodos para preparar sintéticamente los compuestos deformula (1) y sales de adicion farmacéuticamente aceptables de los mismos y un método para reducir el recuento de plaquetas en un paciente mediante laadministracion al paciente de una canti dad efectiva reductora de plaquetas de un compuesto de la formula (1) preferentemente junto con un portadorfarmacéuticamente aceptable. También se proporciona una composicion farmacéutica que contiene un compuesto de formula (1) como ingrediente acti vo junto conexcipientes farmacéuticamente aceptables. Además se proporciona un compuesto de formula (1) para uso en terapia y el uso de un compuesto de formlula (1) parapreparar un medicamento para reducir el recuento de plaquetas en un paciente.
ARP000106257A 1999-11-30 2000-11-28 ''3-4-dihidroquinazolinas 5,6-disustituidas'' AR026631A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/452,008 US6194420B1 (en) 1999-11-30 1999-11-30 2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
AR026631A1 true AR026631A1 (es) 2003-02-19

Family

ID=23794633

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106257A AR026631A1 (es) 1999-11-30 2000-11-28 ''3-4-dihidroquinazolinas 5,6-disustituidas''

Country Status (6)

Country Link
US (1) US6194420B1 (es)
AR (1) AR026631A1 (es)
AU (1) AU1538101A (es)
CA (1) CA2392630C (es)
UY (1) UY26459A1 (es)
WO (1) WO2001040196A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10301105B4 (de) * 2003-01-09 2005-11-24 Chemisch-Pharmazeutisches Labor, Rolf Sachse Gmbh Verwendung von 2-Amino-2H-chinazolin-Derivaten zur Behandlung von myeloproliferativen Erkrankungen, Bluthochdruck und Bronchodilation
OA13018A (en) * 2003-01-23 2006-11-10 Shire Holings Ag Formulation and methods for the treatment of thrombocythemia.
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
US20060030574A1 (en) * 2004-08-04 2006-02-09 Shire Holdings Ag Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
ATE411299T1 (de) * 2005-06-27 2008-10-15 Hoffmann La Roche Chlorsubstituierte guanidine
GB0623749D0 (en) * 2006-11-28 2007-01-10 Shire Llc Substituted quinazolines
US8304420B2 (en) * 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
US7910597B2 (en) * 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
US11826544B2 (en) * 2017-10-26 2023-11-28 Osaa Innovation Aps Assembly for dispensing a liquid comprising an apparatus and a compressible bag
AU2021264980A1 (en) 2020-04-30 2022-12-22 Osaa Innovation Aps An assembly and a system suitable for dispensing a liquid from a compressible bag

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2862966A (en) 1958-12-02 archo
USRE31617E (en) 1972-02-04 1984-06-26 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
US3932407A (en) 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
US4146718A (en) 1978-04-10 1979-03-27 Bristol-Myers Company Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides
US4208521A (en) 1978-07-31 1980-06-17 Bristol-Myers Company Process for the preparation of imidazo[2,1-b]quinazolinones
US4357330A (en) 1981-07-30 1982-11-02 Bristol-Myers Company Pharmaceutical compositions
CA2171073A1 (en) * 1995-12-04 1997-06-05 Philip C. Lang Process for the preparation of ethyl-n-(2,3 dichloro-6- nitrobenzyl) glycine

Also Published As

Publication number Publication date
WO2001040196A1 (en) 2001-06-07
UY26459A1 (es) 2001-06-29
US6194420B1 (en) 2001-02-27
CA2392630C (en) 2010-01-26
AU1538101A (en) 2001-06-12
CA2392630A1 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
GEP20053673B (en) Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
TNSN06032A1 (en) Pyridazine derivatives and their use as therapeutic agents
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
AR054064A1 (es) Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
SE9901573D0 (sv) New compounds
SE9900961D0 (sv) Novel compounds
AR006598A1 (es) "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
GEP20033079B (en) Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency
AR019053A1 (es) Uso de 2'2'-difluoronucleosidos para la preparacion de un medicamento y composicion farmaceutica y producto farmaceutico que los contienen
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
AR026631A1 (es) ''3-4-dihidroquinazolinas 5,6-disustituidas''
SE0002476D0 (sv) New compounds
SE0102440D0 (sv) New compound
UA83832C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и их применение
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
DE69401502D1 (de) Arzneizubereitung zum Herstellen eines stabilisierten Pulvers das eine Kombination aus Acetylsalicylsäure und Metoclopramid als Wirkstoff enthält
NO912414D0 (no) Forbindelse med mavesyreinhiberende effekt og fremgangsmaate for dens fremstilling.
SE9901572D0 (sv) New compounds
MX9304197A (es) Nuevo uso de dimero de lisozina y composiciones que lo contienen.
CA2450915A1 (en) Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure
CA2493208A1 (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
YU107692A (sh) Sulfonamidi i postupak za njihovo dobijanje

Legal Events

Date Code Title Description
FB Suspension of granting procedure